Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 53 54 6 42 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
MeSH 43 D001037
UMLS 71 C0003537

Summaries for Aphasia

NINDS : 53 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Individuals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to epilepsy-aphasia spectrum and frontotemporal lobar degeneration with tdp43 inclusions, grn-related, and has symptoms including seizures, tremor and fever. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Levodopa and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 42 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 466)
# Related Disease Score Top Affiliating Genes
1 epilepsy-aphasia spectrum 34.8 GRIN2A CNKSR2
2 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.6 MAPT GRN
3 nominal aphasia 34.4 TARDBP MAPT GRN CHMP2B C9orf72 APOE
4 progressive non-fluent aphasia 34.4 TBK1 PSEN1 MAPT GRN CHMP2B C9orf72
5 landau-kleffner syndrome 34.0 SRPX2 GRIN2A CNKSR2
6 gerstmann syndrome 33.6 PSEN1 PRNP MAPT APOE
7 semantic dementia 33.5 TARDBP PSEN1 MAPT GRN CHMP2B C9orf72
8 agraphia 32.8 TARDBP PRNP MAPT GRN C9orf72
9 apraxia 32.7 PSEN1 MAPT GRN FOXP2 C9orf72 APOE
10 inclusion body myopathy with paget disease of bone and frontotemporal dementia 32.0 TARDBP OPTN GRN CHMP2B C9orf72
11 frontotemporal dementia 31.9 TBK1 TARDBP SNCA PSEN1 PRNP MAPT
12 alexia 31.7 MAPT GRN APOE
13 supranuclear palsy, progressive, 1 31.6 TARDBP SNCA PSEN1 PRNP MAPT LRRK2
14 corticobasal degeneration 31.5 TARDBP MAPT LRRK2
15 pick disease of brain 31.5 TARDBP SNCA PSEN1 PRNP OPTN MAPT
16 dysgraphia 31.5 TARDBP MAPT GRN CHMP2B C9orf72
17 ideomotor apraxia 31.4 TARDBP MAPT GRN
18 amnestic disorder 31.2 PSEN1 BDNF APP APOE
19 speech disorder 31.2 TARDBP MAPT GRN GRIN2A FOXP2 C9orf72
20 visual agnosia 31.2 PSEN1 MAPT GRN APOE
21 echolalia 31.1 MAPT GRN FOXP2 C9orf72
22 brain injury 31.0 MAPT BDNF APOE
23 anosognosia 31.0 C9orf72 APOE
24 posterior cortical atrophy 31.0 MAPT APOE
25 stroke, ischemic 30.9 PSEN1 MAPT BDNF APOE
26 epilepsy 30.9 SRPX2 MAPT GRIN2A GRIN1 BDNF APP
27 tremor 30.9 SNCA MAPT LRRK2
28 mutism 30.8 TARDBP PRNP MAPT GRN GRIN2A CHMP2B
29 dyscalculia 30.8 TARDBP GRN CHMP2B
30 lateral sclerosis 30.8 TBK1 TARDBP OPTN CHMP2B C9orf72
31 creutzfeldt-jakob disease 30.8 SNCA PRNP MAPT BDNF APP APOE
32 meningoencephalitis 30.8 PSEN1 BDNF APP
33 associative agnosia 30.7 TARDBP MAPT GRN CHMP2B C9orf72
34 primary lateral sclerosis, adult, 1 30.7 SNCA MAPT
35 anxiety 30.6 GRIN2A BDNF APP APOE
36 cerebral degeneration 30.6 MAPT L1CAM APP APOE
37 akinetic mutism 30.6 TARDBP PRNP MAPT
38 prosopagnosia 30.6 TARDBP MAPT GRN CHMP2B C9orf72
39 early-onset, autosomal dominant alzheimer disease 30.3 PSEN1 APP
40 simultanagnosia 30.3 MAPT APOE
41 multiple system atrophy 1 30.3 SNCA PRNP MAPT LRRK2
42 lrrk2 parkinson disease 30.3 SNCA LRRK2
43 benign epilepsy with centrotemporal spikes 30.3 SRPX2 GRIN2A GRIN1 FOXP2 BDNF
44 movement disease 30.3 TARDBP SNCA MAPT LRRK2 C9orf72
45 basal ganglia calcification 30.3 PSEN1 MAPT APP
46 speech and communication disorders 30.3 TARDBP SRPX2 PSEN1 MAPT GRN GRIN2A
47 hydrocephalus, normal-pressure 30.3 PSEN1 MAPT APP APOE
48 motor neuron disease 30.2 TBK1 TARDBP SNCA OPTN MAPT GRN
49 ocular dominance 30.2 GRIN2A GRIN1 BDNF
50 vascular dementia 30.2 PSEN1 PRNP MAPT GRIN2A APP APOE

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


seizures, tremor, fever, dyspnea, edema, cachexia, back pain, vertigo, pain, headache, syncope, scanning speech, cyanosis, chronic pain, sciatica, sore throat, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, vertigo/dizziness, sleeplessness, other symptoms involving head and neck, swelling, mass, or lump in head and neck, aprosodia, aphasic, symptoms involving head and neck, other and unspecified speech disturbances, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 APOE APP BDNF C9orf72 CNKSR2 GRIN1
2 cellular MP:0005384 10.34 APOE APP BDNF C9orf72 GRIN1 GRN
3 homeostasis/metabolism MP:0005376 10.32 APOE APP BDNF C9orf72 GRIN1 GRN
4 mortality/aging MP:0010768 10.31 APOE APP BDNF C9orf72 CHMP2B GRIN1
5 growth/size/body region MP:0005378 10.29 APOE APP BDNF C9orf72 GRIN1 GRN
6 nervous system MP:0003631 10.27 APOE APP BDNF C9orf72 CHMP2B GRIN1
7 integument MP:0010771 10.25 APOE APP BDNF C9orf72 GRIN2A GRN
8 hematopoietic system MP:0005397 10.24 APOE APP C9orf72 GRIN1 GRN LRRK2
9 immune system MP:0005387 10.23 APOE APP C9orf72 GRN LRRK2 MAPT
10 no phenotypic analysis MP:0003012 10.17 APOE APP BDNF C9orf72 GRIN1 GRN
11 reproductive system MP:0005389 9.81 APOE APP BDNF GRIN1 GRN L1CAM
12 renal/urinary system MP:0005367 9.8 APOE GRN LRRK2 MAPT PSEN1 SNCA
13 taste/olfaction MP:0005394 9.35 APOE BDNF GRIN1 MAPT SNCA
14 vision/eye MP:0005391 9.28 APOE BDNF CHMP2B GRIN1 GRN L1CAM

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levodopa Approved Phase 4 59-92-7 6047
2
Memantine Approved, Investigational Phase 4 19982-08-2 4054
3
Carbidopa Approved Phase 4 28860-95-9 34359
4
Citalopram Approved Phase 4 59729-33-8 2771
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Topiramate Approved Phase 4 97240-79-4 5284627
8
Atorvastatin Approved Phase 4 134523-00-5 60823
9
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
10
Corticosterone Experimental Phase 4 50-22-6 5753
11 Anticonvulsants Phase 4
12 Sympathomimetics Phase 4
13 Cholinergic Agents Phase 4
14 Excitatory Amino Acid Antagonists Phase 4
15 Excitatory Amino Acids Phase 4
16 Carbidopa, levodopa drug combination Phase 4
17 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
18 Serotonin Uptake Inhibitors Phase 4
19 Muscarinic Antagonists Phase 4
20 Psychotropic Drugs Phase 4
21 Parasympatholytics Phase 4
22 Antidepressive Agents Phase 4
23 Cholinergic Antagonists Phase 4
24 Hypoglycemic Agents Phase 4
25 Adjuvants, Immunologic Phase 4
26 Botulinum Toxins Phase 4
27 Hypolipidemic Agents Phase 4
28 Anticholesteremic Agents Phase 4
29 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
30 Antimetabolites Phase 4
31 Lipid Regulating Agents Phase 4
32 abobotulinumtoxinA Phase 4
33 Acetylcholine Release Inhibitors Phase 4
34 Neuromuscular Agents Phase 4
35 Botulinum Toxins, Type A Phase 4
36 Fluorodeoxyglucose F18 Phase 4
37 Anti-Inflammatory Agents Phase 4
38 Pharmaceutical Solutions Phase 4
39
Miglustat Approved Phase 3 72599-27-0 51634
40
Donepezil Approved Phase 3 120014-06-4 3152
41
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
42
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
44
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
45 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
46
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Methylene blue Approved, Investigational Phase 3 61-73-4
49
1-Deoxynojirimycin Investigational Phase 3 19130-96-2 1374
50
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 403)
# Name Status NCT ID Phase Drugs
1 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
2 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Aphasia) Completed NCT00102869 Phase 4 levodopa
3 Treatment With Donepezil of Chronic Aphasia and Sensorimotor Deficits Associated to Cerebrovascular Accidents: a Double-Blind,Placebo-Controlled, Randomized Parallel Trial. Completed NCT00196690 Phase 4 Donepezil
4 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Completed NCT00640198 Phase 4 memantine;memantine;placebo
5 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
6 Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction Completed NCT02386475 Phase 4 citalopram;sinemet plus
7 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
8 Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification Completed NCT02225834 Phase 4 Atorvastatin
9 A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care Completed NCT01700387 Phase 4 onabotulinumtoxinA;Topiramate;Placebo
10 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
11 Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
12 A Training and Fidelity Model to Move and Scale Evidence-based Dementia Care and Caregiver Support Programs Into Practice: The Case for COPE in PACE Service Settings Not yet recruiting NCT04165213 Phase 4
13 Randomized, Double Blind, Placebo Controlled, Two Parallel Group Study to Evaluate the Efficacy and Safety of Piracetam, 12 g Intravenous (IV) Infusion Within 7 Hour (h) Post Stroke Onset, Followed by 12 g/d for 4 Weeks (IV Ampoules, Oral Solution) and 4.8 g/d for 8 Weeks (Tablets) in Adult Subjects With an Acute Ischemic Middle Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
14 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
15 COGNITIVE - Comparison of Cognitive Function After Sevoflurane or Propofol Anesthesia for Open-heart Operations Withdrawn NCT00541918 Phase 4 Diprivan (propofol, Astra Zeneca);Sevorane (sevoflurane, Abbott)
16 Improvement of Aphasia After Stroke by Intensive Training and Transcranial Direct Current Stimulation Unknown status NCT00822068 Phase 2, Phase 3
17 Effects of Repetitive Magnetic Transcranial Stimulation of Low Frequency on Speech Production in Patients With Non-fluent Aphasia Post-ischemic Stroke Unknown status NCT02241213 Phase 3
18 Augmenting Language Therapy for Aphasia: A Randomized Double-Blind Placebo-Controlled Trial of Levodopa in Combination With Speech-Language Therapy Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
19 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
20 An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
21 A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
22 Behavioral and Neural Correlates of Melodic-Intonation-Therapy (MIT) and Speech-Repetition-Therapy (SRT) for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
23 Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia Recruiting NCT04134416 Phase 3 Donepezil
24 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
25 Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
26 Multicenter Study of Non-invasive Repetitive Paraorbital Alternating Current Stimulation of the Brain: Therapy for Aphasy Terminated NCT01277575 Phase 3
27 An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
28 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
29 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Unknown status NCT01221779 Phase 2
30 A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
31 Effectiveness of Rehabilitation (Phasic Alerting and Visual Spatial Scanning Training) on the Recovery of Patients Post Right Stroke With Unilateral Spatial Neglect: Using Functional Imaging PET and Standardized Neurobehavioral and Functional Tests Unknown status NCT00305513 Phase 2
32 Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes Completed NCT01686373 Phase 2
33 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
34 Effect Of Verb Network Strengthening Treatment on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
35 Psychosocial Wellbeing Following Stroke: Developing and Testing a Psychosocial Nursing Intervention for Primary Care Completed NCT01912014 Phase 1, Phase 2
36 A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls. Completed NCT01890343 Phase 2 florbetapir 18F;18F-FDG
37 Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase Completed NCT02514044 Phase 2 Dexedrine;Placebo
38 An Open Pilot Study to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Pick's Disease/Frontotemporal Dementia /Pick Complex Completed NCT00416169 Phase 2 galantamine hydrobromide
39 A Feasibility Trial to Evaluate the MindFrame System in the Recanalization of Occluded Vessels in Patients Experiencing an Ischemic Stroke Completed NCT00810095 Phase 2
40 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Completed NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
41 Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Completed NCT02676843 Phase 2 18F-AV-1451
42 Open-label, Exploratory Study of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Naming and Verbal Fluency in Patients With Alzheimer's Disease With Functional Imaging Correlates Completed NCT00814697 Phase 2
43 Double-blind, Parallel Group, Placebo-controlled Trial of the Efficacy and Tolerability of Memantine (20 mg) in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine
44 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
45 Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor Completed NCT00730314 Phase 1, Phase 2
46 Investigation of the Dopamine System in Frontotemporal Dementia Completed NCT00604591 Phase 2 Tolcapone;Placebo
47 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
48 Targeted Transcranial Electrotherapy for Stroke Rehabilitation - Exploratory Trial on Aphasia Recruiting NCT02540109 Phase 2
49 A Phase II, Randomized Blinded Study of the Effects of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the Treatment of Chronic Aphasia Recruiting NCT03651700 Phase 2
50 A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia Recruiting NCT03260920 Phase 2 Syntocinon

Search NIH Clinical Center for Aphasia

Cochrane evidence based reviews: aphasia

Genetic Tests for Aphasia

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

40
Brain, Testes, Cortex, Temporal Lobe, Eye, Thalamus, Liver

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 12429)
# Title Authors PMID Year
1
Effects of a short educational program about aphasia (SEPA) on the burden and quality of life of family caregivers of people with aphasia. 42 61
31483043 2019
2
Assessment of the quality and content of clinical practice guidelines for post-stroke rehabilitation of aphasia. 42 61
31374031 2019
3
Evaluation of a community of practice for speech-language pathologists in aphasia rehabilitation: a logic analysis. 42 61
31358002 2019
4
Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia. 61 54
20400120 2010
5
Expanding the phenotypic spectrum of L1CAM-associated disease. 61 54
16650080 2006
6
First case of L1CAM gene mutation identified in MASA syndrome in Asia. 61 54
15904436 2005
7
A silent mutation, C924T (G308G), in the L1CAM gene results in X linked hydrocephalus (HSAS). 54 61
9643285 1998
8
Identification of novel L1CAM mutations using fluorescence-assisted mismatch analysis. 61 54
9744477 1998
9
L1CAM mutation in a Japanese family with X-linked hydrocephalus: a study for genetic counseling. 54 61
9440802 1997
10
Postoperative Euglycemic Diabetic Ketoacidosis and Encephalopathy Related to SGLT-2 Inhibitors: A Case Report and Discussion of Diabetes Treatment and "Sweet Pee Encephalopathy" in Perioperative Hospital Management. 61
31839866 2020
11
How biological elements interact with language: The biolinguistic inquiry. 61
31585924 2020
12
Deconstructing Poststroke Delirium in a Prospective Cohort of Patients With Intracerebral Hemorrhage. 61
31567406 2020
13
Effectiveness of language training and non-invasive brain stimulation on oral and written naming performance in Primary Progressive Aphasia: A meta-analysis and systematic review. 61
31811834 2019
14
The contribution of semantic memory to the recognition of basic emotions and emotional valence: Evidence from the semantic variant of primary progressive aphasia. 61
30714843 2019
15
Task-free functional language networks: reproducibility and clinical application. 61
31852732 2019
16
Clinical profile of primary progressive aphasias in a tertiary care centre from India. 61
30642192 2019
17
Mechanical Thrombectomy for Middle Cerebral Artery Occlusion Suspected of Ovarian Hyperstimulation Syndrome: Case Report and Review of the Literature. 61
31525479 2019
18
Constraint-induced or multi-modal personalized aphasia rehabilitation (COMPARE): A randomized controlled trial for stroke-related chronic aphasia. 61
31496440 2019
19
Degenerative and Vascular Fluent Aphasia: Looking for Differences. 61
31800483 2019
20
Taking the classroom to camp: The facilitators' role in creating an impactful interprofessional experiential learning opportunity. 61
31829776 2019
21
Category specific recall in acute stroke: a case with letter speech. 61
31571518 2019
22
Effects of semantic neighbourhood density on spoken word production. 61
31184282 2019
23
The utility of lesion classification in predicting language and treatment outcomes in chronic stroke-induced aphasia. 61
31093842 2019
24
Single Word Repetition Predicts Long-Term Outcome of Aphasia Caused by an Ischemic Stroke. 61
31836358 2019
25
Restoring Speech Using Neuroprosthetic Technology: A New Frontier for Patients with Aphasia. 61
31810144 2019
26
Time reference, morphology and prototypicality: tense production in stroke aphasia and semantic dementia in Greek. 61
31818150 2019
27
How Responsiveness From a Communication Partner Affects Story Retell in Aphasia: Quantitative and Qualitative Findings. 61
31851828 2019
28
When Words Fail: Providing Effective Psychological Treatment for Depression in Persons with Aphasia. 61
30778804 2019
29
Thrombolysis' benefits on early post-stroke language recovery in aphasia patients. 61
31439485 2019
30
Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations. 61
31626288 2019
31
Perturbations of language network connectivity in primary progressive aphasia. 61
31530376 2019
32
Dementia trajectory for patients with logopenic variant primary progressive aphasia. 61
31332581 2019
33
Taxonomic Interference Associated with Phonemic Paraphasias in Agrammatic Primary Progressive Aphasia. 61
31800048 2019
34
Does surface dyslexia/dysgraphia relate to semantic deficits in the semantic variant of primary progressive aphasia? 61
31682928 2019
35
[18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window. 61
31535269 2019
36
Audiovisual speech segmentation in post-stroke aphasia: a pilot study. 61
31369358 2019
37
Treatment-related changes in neural activation vary according to treatment response and extent of spared tissue in patients with chronic aphasia. 61
31627014 2019
38
Effect of Anodal tDCS on Articulatory Accuracy, Word Production, and Syllable Repetition in Subjects with Aphasia: A Crossover, Double-Blinded, Sham-Controlled Trial. 61
31432434 2019
39
Neural structures supporting spontaneous and assisted (entrained) speech fluency. 61
31580418 2019
40
Performance differences between aphasia and healthy aging on an executive function test battery. 61
31786959 2019
41
Multifocal Stroke From Ozone Gas Emboli. 61
30741783 2019
42
The Cerebellum in Frontotemporal Dementia: a Meta-Analysis of Neuroimaging Studies. 61
31428914 2019
43
A meta-analysis of neuropsychological, social cognitive, and olfactory functioning in the behavioral and language variants of frontotemporal dementia. 61
30520407 2019
44
Patient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy. 61
31623919 2019
45
Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. 61
31848674 2019
46
Vision, Aphasia, Neglect Assessment to Predict Neurosurgical Intervention in Patients with Nontraumatic Intracerebral Hemorrhage. 61
31680030 2019
47
Functional MRI provides insights into language organization of bilingual aphasia. 61
31818993 2019
48
Incidence and Symptomatology of Vascular Crossed Aphasia in Bengali. 61
31800486 2019
49
Empirical Evaluation of Computer-Adaptive Alternate Short Forms for the Assessment of Anomia Severity. 61
31851861 2019
50
Transient cerebral vasospasm after carotid artery stenting: A case report and literature review. 61
31837494 2019

Variations for Aphasia

ClinVar genetic disease variations for Aphasia:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(12;14)(q15;q13)matTranslocation Uncertain significance 267936

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

Pathways for Aphasia

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.44 TBK1 TARDBP SRPX2 SNCA PSEN1 PRNP
2 extracellular space GO:0005615 10.24 SRPX2 SNCA LRRK2 GRN C9orf72 BDNF
3 Golgi apparatus GO:0005794 10.19 SNCA PSEN1 PRNP OPTN LRRK2 GRN
4 cell projection GO:0042995 10.14 PSEN1 MAPT LRRK2 L1CAM GRIN2A C9orf72
5 cell junction GO:0030054 10.11 SRPX2 SNCA PSEN1 LRRK2 GRIN2A GRIN1
6 synapse GO:0045202 10.11 SRPX2 SNCA PSEN1 LRRK2 GRIN2A GRIN1
7 cytoplasmic vesicle GO:0031410 10.1 PSEN1 OPTN LRRK2 GRIN2A C9orf72 BDNF
8 endosome GO:0005768 10.05 PSEN1 OPTN LRRK2 GRN CHMP2B C9orf72
9 cell surface GO:0009986 10.04 SRPX2 PSEN1 PRNP L1CAM GRIN2A GRIN1
10 lysosome GO:0005764 10.01 SNCA LRRK2 GRN CHMP2B C9orf72
11 cell GO:0005623 10 SNCA PSEN1 PRNP MAPT LRRK2 GRN
12 neuronal cell body GO:0043025 9.98 SNCA PSEN1 MAPT LRRK2 L1CAM CNKSR2
13 postsynaptic density GO:0014069 9.97 PRNP GRIN2A GRIN1 CNKSR2 CHMP2B
14 neuron projection GO:0043005 9.97 PSEN1 MAPT LRRK2 GRIN2A GRIN1 CNKSR2
15 membrane raft GO:0045121 9.95 PSEN1 PRNP MAPT LRRK2 APP
16 glutamatergic synapse GO:0098978 9.95 LRRK2 GRIN2A GRIN1 CNKSR2 CHMP2B APOE
17 axon GO:0030424 9.92 SNCA PSEN1 MAPT LRRK2 L1CAM C9orf72
18 dendritic spine GO:0043197 9.89 MAPT GRIN2A GRIN1 APP
19 dendrite GO:0030425 9.81 PSEN1 PRNP MAPT LRRK2 L1CAM GRIN1
20 rough endoplasmic reticulum GO:0005791 9.79 SNCA PSEN1 APP
21 terminal bouton GO:0043195 9.78 SNCA LRRK2 GRIN1
22 synaptic membrane GO:0097060 9.71 SRPX2 PSEN1 GRIN2A GRIN1
23 inclusion body GO:0016234 9.7 SNCA PRNP LRRK2
24 synaptic cleft GO:0043083 9.64 GRIN1 APOE
25 ciliary rootlet GO:0035253 9.63 PSEN1 APP
26 main axon GO:0044304 9.63 MAPT C9orf72 APP
27 NMDA selective glutamate receptor complex GO:0017146 9.62 GRIN2A GRIN1
28 growth cone GO:0030426 9.5 SNCA PSEN1 MAPT LRRK2 L1CAM C9orf72
29 synaptic vesicle GO:0008021 9.17 SNCA PSEN1 LRRK2 GRIN2A GRIN1 BDNF

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 10 SNCA PSEN1 APP APOE
2 regulation of gene expression GO:0010468 10 TBK1 PSEN1 LRRK2 APP APOE
3 negative regulation of gene expression GO:0010629 9.97 TBK1 TARDBP PSEN1 MAPT APP APOE
4 autophagy GO:0006914 9.96 PSEN1 OPTN LRRK2 CHMP2B C9orf72
5 neuron projection development GO:0031175 9.94 MAPT L1CAM APP APOE
6 cellular calcium ion homeostasis GO:0006874 9.91 PSEN1 GRIN1 APOE
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.89 TBK1 SNCA APP
8 calcium-mediated signaling GO:0019722 9.89 LRRK2 GRIN2A GRIN1
9 cerebral cortex development GO:0021987 9.88 PSEN1 GRIN1 FOXP2
10 regulation of autophagy GO:0010506 9.88 MAPT LRRK2 C9orf72
11 forebrain development GO:0030900 9.87 PSEN1 FOXP2 APP
12 positive regulation of protein binding GO:0032092 9.87 PSEN1 LRRK2 APP
13 learning GO:0007612 9.87 GRIN2A GRIN1 APP
14 negative regulation of neuron death GO:1901215 9.85 SNCA LRRK2 APOE
15 excitatory postsynaptic potential GO:0060079 9.85 SNCA LRRK2 GRIN2A GRIN1
16 response to oxidative stress GO:0006979 9.85 PSEN1 PRNP LRRK2 APP APOE
17 adult locomotory behavior GO:0008344 9.83 SNCA GRIN1 APP
18 visual learning GO:0008542 9.83 GRIN2A GRIN1 APP
19 regulation of synaptic plasticity GO:0048167 9.83 PSEN1 MAPT GRIN2A GRIN1
20 memory GO:0007613 9.83 PSEN1 MAPT GRIN2A GRIN1 BDNF
21 positive regulation of neuron death GO:1901216 9.82 SNCA PRNP MAPT
22 long-term memory GO:0007616 9.81 PRNP GRIN1 APOE
23 regulation of NMDA receptor activity GO:2000310 9.8 GRIN2A GRIN1 APP
24 microglial cell activation GO:0001774 9.8 SNCA MAPT APP
25 negative regulation of neuron apoptotic process GO:0043524 9.8 SNCA PSEN1 GRN GRIN1 BDNF APOE
26 cellular response to copper ion GO:0071280 9.79 SNCA PRNP APP
27 ionotropic glutamate receptor signaling pathway GO:0035235 9.77 GRIN2A GRIN1 APP
28 regulation of long-term neuronal synaptic plasticity GO:0048169 9.77 SNCA GRIN1 APP
29 regulation of neuronal synaptic plasticity GO:0048168 9.76 SNCA GRIN1 APOE
30 regulation of neuron death GO:1901214 9.75 TBK1 SNCA LRRK2
31 astrocyte activation GO:0048143 9.74 PSEN1 MAPT APP
32 stress granule assembly GO:0034063 9.73 MAPT C9orf72
33 startle response GO:0001964 9.73 GRIN2A GRIN1
34 positive regulation of receptor recycling GO:0001921 9.73 SNCA PSEN1
35 axon development GO:0061564 9.73 MAPT L1CAM
36 dopamine metabolic process GO:0042417 9.73 SNCA GRIN2A
37 negative regulation of protein processing GO:0010955 9.73 PRNP LRRK2
38 cellular copper ion homeostasis GO:0006878 9.72 PRNP APP
39 negative regulation of amyloid-beta formation GO:1902430 9.72 PRNP APOE
40 supramolecular fiber organization GO:0097435 9.72 SNCA MAPT
41 suckling behavior GO:0001967 9.72 GRIN1 APP
42 amyloid fibril formation GO:1990000 9.71 MAPT APP
43 locomotory exploration behavior GO:0035641 9.71 LRRK2 APOE
44 amyloid precursor protein metabolic process GO:0042982 9.71 PSEN1 APOE
45 negative regulation of long-term synaptic potentiation GO:1900272 9.71 PRNP APP APOE
46 cellular response to manganese ion GO:0071287 9.7 LRRK2 APP
47 excitatory chemical synaptic transmission GO:0098976 9.69 GRIN2A GRIN1
48 neuron projection maintenance GO:1990535 9.69 PSEN1 PRNP APP
49 regulation of mitochondrial fission GO:0090140 9.68 MAPT LRRK2
50 intracellular distribution of mitochondria GO:0048312 9.68 MAPT LRRK2

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TBK1 TARDBP SRPX2 SNCA PSEN1 PRNP
2 microtubule binding GO:0008017 9.76 SNCA PRNP MAPT LRRK2
3 chaperone binding GO:0051087 9.69 PRNP MAPT GRN
4 calcium channel activity GO:0005262 9.67 PSEN1 GRIN2A GRIN1
5 tubulin binding GO:0015631 9.54 PRNP MAPT LRRK2
6 ionotropic glutamate receptor activity GO:0004970 9.48 GRIN2A GRIN1
7 amyloid-beta binding GO:0001540 9.46 PRNP GRIN2A GRIN1 APOE
8 lipoprotein particle binding GO:0071813 9.43 MAPT APOE
9 NMDA glutamate receptor activity GO:0004972 9.4 GRIN2A GRIN1
10 identical protein binding GO:0042802 9.4 TBK1 TARDBP SRPX2 SNCA PRNP OPTN
11 cuprous ion binding GO:1903136 9.32 SNCA PRNP
12 glutamate-gated calcium ion channel activity GO:0022849 9.26 GRIN2A GRIN1

Sources for Aphasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....